Aliskiren Warnings Being Updated

Share this content:

Labels for the aliskiren-containing drugs, Amturnide, Tekturna, Tekturna HCT, Tekamlo, and Valturna, are being updated to warn against the use of the drug with angiotensin receptor blockers (ARBs) or ACE inhibitors in patients with diabetes because of a risk of renal impairment, hypotension, and hyperkalemia.

Also being added is a warning to avoid the use of aliskiren with ARBs or ACE inhibitors in patients with moderate to severe renal impairment (GFR below 60 mL/min/1.73 m2) .

You must be a registered member of Renal and Urology News to post a comment.